ABCC9

Across TCGA pan-cancer cohorts, ABCC9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ABCC9 data layer compared with 26 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ABCC9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ABCC9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

MESO, UCEC, and ACC are the cancer types where ABCC9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	30	view →
UCEC	DFS	Median	All	0.967	0.822	.003	30	view →
ACC	DFS	Median	All	0.207	0.658	.016	6	view →
STAD	DFS	Median	All	0.863	0.644	.032	4	view →
PRAD	DFS	Median	All	0.284	0.781	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ABCC9–MESO (OS)

Open the MESO breakdown →